CUAMC
DNTH icon

China Universal Asset Management Company’s Dianthus Therapeutics DNTH Stock Holding History

China Universal Asset Management Company’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34
Closed -$1K – 415
2022
Q3 		$1K Buy
+34
New +$931 ﹤0.01% 392

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

China Universal Asset Management Company's DNTH Position: Q4 2022 in Review

China Universal Asset Management Company sold out of Dianthus Therapeutics (DNTH) in Q4 2022, closing a stake of 34 shares — an estimated $1K sold.

China Universal Asset Management Company first reported a position in DNTH in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 53 funds tracked by Wall St. Rank hold DNTH as of Q4 2022.

  • China Universal Asset Management Company reported no remaining Dianthus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 34 Dianthus Therapeutics shares in Q4 2022, an estimated $1K.
  • China Universal Asset Management Company first reported a position in Dianthus Therapeutics in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's Dianthus Therapeutics position peaked at $1K in Q3 2022.
  • 53 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.